Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Work In Process (2017 - 2025)

Historic Work In Process for Neurocrine Biosciences (NBIX) over the last 7 years, with Q1 2025 value amounting to $13.8 million.

  • Neurocrine Biosciences' Work In Process rose 1500.0% to $13.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $13.8 million, marking a year-over-year increase of 1500.0%. This contributed to the annual value of $10.9 million for FY2024, which is 1237.11% up from last year.
  • According to the latest figures from Q1 2025, Neurocrine Biosciences' Work In Process is $13.8 million, which was up 1500.0% from $10.9 million recorded in Q4 2024.
  • Neurocrine Biosciences' 5-year Work In Process high stood at $13.8 million for Q1 2025, and its period low was $9.7 million during Q4 2023.
  • Over the past 3 years, Neurocrine Biosciences' median Work In Process value was $11.4 million (recorded in 2024), while the average stood at $11.5 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Work In Process surged by 1237.11% in 2024 and then skyrocketed by 1500.0% in 2025.
  • Over the past 3 years, Neurocrine Biosciences' Work In Process (Quarter) stood at $9.7 million in 2023, then grew by 12.37% to $10.9 million in 2024, then grew by 26.61% to $13.8 million in 2025.
  • Its Work In Process was $13.8 million in Q1 2025, compared to $10.9 million in Q4 2024 and $10.6 million in Q3 2024.